{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:30Z","timestamp":1761059370718},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10952,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1982,8]]},"abstract":"<jats:p>1 Unexpectedly low plasma concentrations of mexiletine were observed in three patients treated with mexiletine and concurrently taking phenytoin. 2 Six healthy volunteers were given a single oral dose of mexiletine (400 mg), before and after 1 week of phenytoin administration (300 mg\/day). 3 The mean +\/\u2010 s.d. area under the plasma mexiletine concentration\u2010time curve decreased from 17.67 +\/\u2010 6.21 to 8.01 +\/\u2010 3.64 micrograms ml\u20101 h (P less than 0.003). 4 The mean +\/\u2010 s.d. half\u2010life of elimination of mexiletine decreased from 17.2 +\/\u2010 5.26 to 8.4 +\/\u2010 4.17 h (P less than 0.02) 5 The suggested mechanism of the interaction is hepatic mixed\u2010function oxidase enzyme induction by phenytoin. 6 The interaction is likely to be clinically significant.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1982.tb01965.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T16:52:09Z","timestamp":1343321529000},"page":"219-223","source":"Crossref","is-referenced-by-count":42,"title":["Enhanced metabolism of mexiletine after phenytoin administration."],"prefix":"10.1111","volume":"14","author":[{"given":"EJ","family":"Begg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PM","family":"Chinwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RO","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DN","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb00535.x"},{"issue":"1","key":"e_1_2_1_3_1","first-page":"60","article-title":"The distribution of mexiletine in man.","volume":"53","author":"BECKETT A.H.","year":"1977","journal-title":"Postgrad. med. J."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92271-X"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb00868.x"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb00833.x"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197917030-00003"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197603252941305"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6094.1061"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb04717.x"},{"issue":"1","key":"e_1_2_1_11_1","first-page":"56","article-title":"Variable pharmacokinetics of mexiletine.","volume":"53","author":"KAYE C.M.","year":"1977","journal-title":"Postgrad. med. J."},{"issue":"1","key":"e_1_2_1_12_1","first-page":"48","article-title":"Measurement of plasma mexiletine concentrations.","volume":"53","author":"KELLY J.G.","year":"1977","journal-title":"Postgrad. med. J."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1974.tb00214.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb05904.x"},{"issue":"1","key":"e_1_2_1_15_1","first-page":"50","article-title":"Absorption, distribution and elimination of mexiletine.","volume":"53","author":"PRESCOTT L.F.","year":"1977","journal-title":"Postgrad. med. J."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01286.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600610111"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92270-8"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975184377"},{"key":"e_1_2_1_20_1","first-page":"505","article-title":"The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.","volume":"9","author":"WING L.M.H.","year":"1980","journal-title":"Br. J. clin. Pharmac."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1982.tb01965.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1982.tb01965.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:55:41Z","timestamp":1699703741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1982.tb01965.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1982,8]]}},"alternative-id":["10.1111\/j.1365-2125.1982.tb01965.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb01965.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,8]]}}}